1. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391-479.

  2. Young JB. The global epidemiology of heart failure. Med Clin North Am 2004; 88:1135-1143, ix.

  3. Neumann T, Biermann J, Erbel R, et al. Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int 2009; 106:269-275.

  4. Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. Heart Fail Rev 2007; 12:91-95.

  5. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388-2442.

  6. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002; 4:361-371.

  7. Remme WJ, McMurray JJ, Rauch B, et al. Public awareness of heart failure in Europe: first results from SHAPE. Eur Heart J 2005; 26:2413-2421.

  8. Mann DL. Heart failure and cor pulmonale. In: Fauci AS, Braunwald E, Kasper DL, et al., eds. Harrison's principles of internal medicine. New York: Mc Graw Hill, 2008; 1443-1455.

  9. Wollert KC, Drexler H. Herzinsuffizienz. In: Gerok W, Huber C, Meinertz T, Zeidler H, eds. Die Innere Medizin. Stuttgart: Schattauer, 2007; 101-116.

  10. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24:442-463.

  11. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24:464-474.

  12. Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. Boston: Little, Brown & Co, 1994.

  13. Fleg JL, Pina IL, Balady GJ, et al. Assessment of functional capacity in clinical and research applications: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association. Circulation 2000; 102:1591-1597.

  14. Hoppe UC, Bohm M, Dietz R, et al. Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 2005; 94:488-509.

  15. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115-1140.

  16. Januzzi JL, Jr., Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 2008; 101:29-38.

  17. Fuat A, Murphy JJ, Hungin AP, et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006; 56:327-333.

  18. Moe GW, Howlett J, Januzzi JL, Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007; 115:3103-3110.

  19. Spanuth E. Das natriuretische Peptid NT-proBNP in der kardiologischen Diagnostik. Symposion MEDICAL Kardiologie und Diabetologie14./15. Jahrgang 2004; Sonderdruck.

  20. Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003; 42:1793-1800.

  21. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. Bmj 2003; 326:196.

  22. Mueller C, Breidthardt T, Laule-Kilian K, Christ M, Perruchoud AP. The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly 2007; 137:4-12.

  23. Roche. Packungsbeilage Elecsys® proBNP. 2009.

  24. Nicholls MG, Richards AM. Disease monitoring of patients with chronic heart failure. Heart 2007; 93:519-523.

  25. Lee DS, Vasan RS. Goals and guidelines for treating hypertension in a patient with heart failure. Curr Treat Options Cardiovasc Med 2006; 8:334-344.

  26. Siebert U, Januzzi JL, Jr., Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 2006; 98:800-805.

  27. O'Donoghue M, Kenney P, Oestreicher E, et al. Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study). Am J Cardiol 2007; 100:1336-1340.

  28. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK. Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. Heart 2004; 90:866-870.

  29. Schocken DD, Benjamin EJ, Fonarow GC, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2008; 117:2544-2565.

  30. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. Jama 2007; 297:169-176.

  31. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification
    of patients with chest pain and non ST-segment elevation. J Am Coll Cardiol 2002; 40:437-445.

  32. West MJ, Nestel PJ, Kirby AC, et al. The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study. Eur Heart J 2008; 29:923-931.

  33. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110:2168-2174.

  34. Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006; 114:201-208.

  35. Magne J, Dubois M, Champagne J, et al. Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy. Cardiovasc Ultrasound 2009; 7:39.

  36. Green SM, Green JA, Januzzi JL, Jr. Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting. Am J Ther 2009; 16:171-177.

  37. Bayes-Genis A, Pascual-Figal D, Fabregat J, et al. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. Int J Cardiol 2007; 120:338-343.

  38. Gustafsson F, Badskjaer J, Hansen FS, Poulsen AH. Value of N-terminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography. Heart Drug 2003; 3:141-146.

  39. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 49:1733-1739.

  40. Knebel F, Schimke I, Pliet K, et al. NT-ProBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail 2005; 11:S38-41.

  41. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126-1130.

  42. Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005; 7:537-541.

  43. Disomma S, Magrini L, Pittoni V, Marino R, Peacock WF, Maisel A. Usefulness of serial assessment of natriuretic peptides in the emergency department for patients with acute decompensated heart failure. Congest Heart Fail 2008; 14:21-24.

  44. Luchner A, Holmer S, Schunkert H, Riegger GA. Bedeutung der Herzinsuffizienzmarker BNP und NT-proBNP für die Klinik. Dt Aerzteblatt 2003; 100:A3314-3321.

  45. Lee SC, Stevens TL, Sandberg SM, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002; 8:149-154.

  46. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009; 158:422-430.

  47. Di Somma S, Magrini L, Mazzone M, et al. Decrease in NTproBNP plasma levels indicates clinical improvement of acute decompensated heart failure. Am J Emerg Med 2007; 25:335-339.

  48. Saurbier B, Bode C. Krankheiten des Koronarkreislaufs. In: Gerok W, Huber C, Meinertz T, Zeidler H, eds. Die Innere Medizin. Stuttgart: Schattauer, 2007; 138-163.

  49. Libby P. The pathogenesis, prevention, and treatment of atherosclerosis. In: Fauci AS, Braunwald E, Kasper DL, et al., eds. Harrison's principles of internal medicine. New York: Mc Graw Hill, 2008; 1501-1509.

  50. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24:1601-1610.

  51. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).
    Eur J Cardiovasc Prev Rehabil 2007; 14 Suppl 2:E1-40.

  52. Hildebrandt P, Richards AM. Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol 2008; 101:21-24.



Sie verlassen nun

Links zu Websites Dritter werden im Sinne des Servicegedankens angeboten. Der Herausgeber äußert keine Meinung über den Inhalt von Websites Dritter und lehnt ausdrücklich jegliche Verantwortung für Drittinformationen und deren Verwendung ab.